Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Alzheimer’s disease (AD) is a progressive neurodegenerative disease and the main cause of dementia, with an estimated prevalence of 50 million people worldwide that is projected to triple by 2050. Masitinib is an orally administered
ROLE OF CALCIUM HOMEOSTASIS IN ALZHEIMER’S DISEASE
Alzheimer’s disease (AD) is a neurodegenerative disease associated with senile plaques (SP) and neurofibrillary tangles (NFTs) in the brain. Abnormal accumulation of a specific protein, β-amyloid (Aβ), in brain neurons plays a central role in the pathogenesis of this neurodegenerative disease. Changes in intracellular calcium signalling are related to Alzheimer’s disease. Studies have demonstrated that […]